Skip to content

ELASMOGEN

discovering and developing soloMERs for the treatment of auto-immune mediated, inflammatory diseases

ELASMOGEN
  • about
    • the team
    • the board
    • investors
  • soloMER technology
    • discovery platform
    • product development options
  • pipeline
    • auto-Immune / anti-Inflammatory
    • oncology
    • NDURE programme
  • partners
    • licensing
    • partnerships and collaborations
  • news
    • press release
    • publications
    • events
  • contact
Press release

Press release

  • Home
  • News
  • Press release
  • Press release
  • Publications
  • Events

News archives

  • May 2022
  • December 2021
  • September 2021
  • January 2021
  • December 2020
  • July 2020
  • May 2020
  • April 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • July 2019
  • May 2019
  • March 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • August 2018
  • May 2018
  • January 2018
  • November 2017
  • May 2017
  • March 2017
  • January 2017
  • July 2016
  • March 2016

BGF, Scottish National Investment Bank and Scottish Enterprise join forces to invest £8m in Aberdeen biologics company Elasmogen | 18.05.2022

Aberdeen, Scotland, 18 May 2022: Elasmogen – a biopharmaceutical company discovering and developing new therapeutics using its unique soloMERTM platform – has secured £8 million investment. The funding round was led by BGF and Scottish National Investment Bank (The Bank), with additional support from existing investor Scottish Enterprise. The multi-million-pound investment will enable Aberdeen-based Elasmogen […]

Shark antibody-like proteins neutralize COVID-19 virus, help prepare for future coronaviruses | 17.12.2021

MADISON – Small, unique antibody-like proteins known as VNARs derived from the immune systems of sharks can prevent the virus that causes COVID-19, its variants, and related coronaviruses from infecting human cells, according to a new study published Dec. 16. The new VNARs will not be immediately available as a treatment in people, but they […]

Researcher in Elasmogen Ltd receives prestigious fellowship worth £2 M to help establish him as a future leader of UK bioscience | 08.09.2021

Expertise in drug discovery and the treatment of life-changing inflammatory diseases has been rewarded with prestigious funding via the UKRI’s Future Leaders Fellowship (FLF) Scheme. Dr Obinna Ubah, heads up Scottish biotechnology company Elasmogen Ltd’s auto-immune and anti-inflammation research efforts, and has received a £2 M research award of which £1.57 M is a grant […]

Elasmogen announces a panel of novel, potent, anti-Covid-19 therapeutic candidates identified through collaboration with U.S. research partners | 25.01.2021

At only one tenth the size of traditional antibodies new VNAR biologics could be used to both treat and protect against SARSCoV-2 infections January 25th 2021: Aberdeen, Scotland:  Elasmogen Ltd, the pioneering biopharmaceutical company leading the development of VNAR and soloMERTM biologics, today announces a significant breakthrough in the identification of next-generation protein-based drugs potentially […]

Elasmogen announces grants of 2 new VNAR and soloMER patent families | 09.12.2020

New grants across multiple territories cover the use of humanised or de-immunised VNARs for therapeutic applications December 9th 2020: Aberdeen, Scotland:  Elasmogen Ltd, the biopharmaceutical company leading the development of soloMERTM biologics, today announces a significant development in its comprehensive intellectual property position as two new patent families go to grant in multiple territories.  These […]

Elasmogen wins two grants worth £374,000 | 08.07.2020

New awards for COVID-19 and oncology programs support re-opening of labs in Aberdeen Aberdeen, UK, 8th July 2020:  Aberdeen drug discovery pioneer, Elasmogen Ltd has won two new grants worth £374,000 to support programs for COVID-19 and oncology.  In April 2020 Elasmogen secured £143,000 from Scottish Government to use their drug discovery platform to accelerate […]

Intract Pharma and Elasmogen Ltd announce collaboration to discover and develop novel, orally-delivered protein therapeutics | 05.05.2020

Intract Pharma Limited London, UK (“Intract”), and Elasmogen Limited, Aberdeen, Scotland (“Elasmogen”) have announced an agreement to collaborate and develop novel orally-delivered protein therapeutics (biologics), incorporating proprietary technologies developed by each of the partners. The collaboration combines Elasmogen’s soloMER™ technology, small (11 kDa) single-chain  binding domains that can be rapidly re-formatted to generate super-neutralizers (bivalent, […]

Elasmogen Ltd to deploy their soloMER technology platform to develop tools to combat COVID-19 | 29.04.2020

29th April 2020; Elasmogen Limited, Aberdeen, Scotland (“Elasmogen”) are to collaborate with the University of Aberdeen as a partner on a Scottish Government research award of almost £1 M to tackle COVID-19.    Current diagnostic testing for COVID-19 so called RT-PCR for infectious agents, whilst accurate is complex to perform, suited to centralised laboratories, takes […]

Elasmogen featured in Biotechnology and Biological Sciences Research Council Spinout report | 26.02.2020

Elasmogen has been featured in BBSRC’s report highlighting a few spinout companies that exemplify BBSRC investments in research.

Elasmogen nominated for Innovative Collaboration award with Almac Discovery | 24.01.2020

Elasmogen has been nominated for a Life Science Award with Almac Discovery in the Innovative Collaboration category. The finalists in the Innovative Collaboration award, sponsored by @MarksClerkScot are announced! They are @ElasmogenLtd , @iCAIRD_Scot , and @MedtronicUK . Find out who wins at #ScotLiSciAwards on 19 March – tickets available at https://t.co/z5f5tnBLNS pic.twitter.com/9Q7SOYezme — LifeScienceAwardScot […]

ELASMOGEN Copyright 2022

Liberty Building | Foresterhill Health Campus | Aberdeen | AB25 2ZP

  • info@elasmogen.com
  • twitter
  • linkedin